Metraipolis › archive › dc_8ba7bfb71d1d

Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people living with HIV in South Africa — Europe PMC PPR:PPR1117071

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR1117071
DOI
10.1101/2025.11.10.25339878
License (as archived)
CC0-1.0
Archived
2026-10-06T08:50:35.657Z
SHA-256 of the archived text
ed3b771f51f7fa2edf2da604e8e8860674bcc8f5836039d61a40c5cad6aa75fa
Stable URL of this page
https://metraipolis.com/documento/dc_8ba7bfb71d1d

How to cite

Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people living with HIV in South Africa — Europe PMC PPR:PPR1117071 — Europe PMC, https://europepmc.org/article/PPR/PPR1117071 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_8ba7bfb71d1d (Metraipolis archive dc_8ba7bfb71d1d, sha256 ed3b771f51f7fa2edf2da604e8e8860674bcc8f5836039d61a40c5cad6aa75fa)
BibTeX
@misc{dc8ba7bfb71d1d,
  title = {Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people living with HIV in South Africa — Europe PMC PPR:PPR1117071},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR1117071},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_8ba7bfb71d1d; sha256 ed3b771f51f7fa2edf2da604e8e8860674bcc8f5836039d61a40c5cad6aa75fa},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR1117071. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Objective: : measures of antiretroviral therapy (ART) adherence, such as tenofovir (TFV) concentrations, may allow for targeted interventions to prevent future HIV viraemia. We evaluated three TFV adherence measures and their association with current and 24-week viral load (VL) outcomes. Methods: In a sub-study of the South African-based POwER trial, we measured urine TFV using a point-of-care (POC) antibody-based assay and two metrics assessed via liquid-chromatography-mass-spectrometry: quantitative urine TFV, and TFV-diphosphate (TFV-DP) concentrations in dried blood spots (DBS). We assessed the association between current and subsequent 24-week VL outcomes and these three measures using logistic regression models. We also compared the baseline characteristics of individuals with detectable vs. undetectable POC urine TFV results at enrolment. Results: Of 124 participants, 54.8% female, median age 39 years, 101 (81.5%) had detectable POC urine TFV and 23 (18.5%) did not. Higher TFV-DP concentrations in DBS were negatively associated with viraemia after 24-weeks (OR 0.83, 95% CI 0.725-0.928, p=0.003), whilst a detectable POC urine TFV (OR 0.62, 95% CI 0.22-1.82, p=0.380) and quantitative urine TFV (OR 0.98, 95% CI 0.95-1.00, p=0.153) showed no significant association. Compared to those with detectable POC urine TFV, those with undetectable POC urine TFV were more likely to be concurrently viraemic at enrolment (78.3% vs 25.7%, p<0.001) and have a CD4 count <200 cells/uL (34.8% vs 12.9%, p=0.001). Conclusion: DBS TFV-DP was associated with viraemia at 24-weeks and could help predict future viraemia. Undetectable POC urine TFV was associated with recent ART initiation, current viraemia, and lower CD4 count. Trial registration: Pan African Clinical Trials Registry (PACTR202001785886049) and the South African Clinical Trials Registry (DOH-27-072020-6890).

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: medRxiv, 2025 (prima pubblicazione 2025-11-11).
Identificativi: DOI 10.1101/2025.11.10.25339878.
Pagina: https://europepmc.org/article/PPR/PPR1117071 — https://doi.org/10.1101/2025.11.10.25339878. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T08:20:26.646Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.